C

Chapel Allerton Hospital | Dermatology Research

Research site

(Unclaimed)

Location

Chapeltown Road, Leeds, Leeds, England

Site insights

Top conditions

Top treatments

Guselkumab

Apremilast

Methotrexate

JNJ-77242113

bupivacaine

BIIB059

CC-4047

Imiquimod

CC-10004

celecoxib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 31 total trials

Locations recently updated

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Enrolling

Scleroderma, Systemic

Drug: Placebo

Drug: Avenciguat (BI 685509)

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Enrolling

Arthritis, Psoriatic

Drug: Placebo

Drug: Guselkumab

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting

Plaque Psoriasis

Drug: JNJ-77242113

Drug: Placebo

A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Drug: BIIB059 (litifilimab)

Drug: Placebo